Plant-derived extracellular vesicles -a novel clinical anti-inflammatory drug carrier worthy of investigation - 04/12/23

Abstract |
Plant-derived extracellular vesicles (PDEVs) have shown remarkable potential as sustainable, green, and efficient drug delivery nanocarriers. As natural nanoparticles containing lipids, protein, nucleic acids and secondary metabolites, they have received widespread attention as a replacement for mammalian exosomes in recent years. In this review, the advances in isolation, identification, composition, therapeutic effect, and clinical application prospect were comprehensively reviewed, respectively. In addition, the specific modification strategies have been listed focusing on the inherent drawbacks of the raw PDEVs like low targeting efficiency and poor homogeneity. With emphasis on their biology mechanism in terms of immune regulation, regulating oxidative stress and promoting regeneration in the anti-inflammatory field and application value demonstrated by citing some typical examples, this review about PDEVs would provide a broad and fundamental vision for the in-depth exploration and development of plant-derived extracellular vesicles in the in-vivo anti-inflammation and even other biomedical applications.
Le texte complet de cet article est disponible en PDF.Abbreviations : ABC, AFM, AMPK, ATPase, cryo-EM, DAG, DC, DLS, DSS, EV, ECM, ERK, GIPCs, GO, GPR161, HaCaT, HIC, HO-1, HPLC, IFN, IL, LPS, MEVs, MAPK, miRNA, MMP, mRNA, mTOR, NF-κB, NQO-1, Nrf2, NSAIDs, NTA, PA, PAGE, PC, PDEVs, PEG, PET, PFKFB3, PG, PI, PKC, PMA, PME, ROS, RNS, SEM, siRNA, STAT, TAG, TEM, TG, TGF, THP, TLC, TLR4/TRIF, TNF-α, TRPS
Keywords : Plant-derived extracellular vesicles, Exosomes, Cargo loading, Anti-inflammation
Plan
Vol 169
Article 115904- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?